(NewsDirect)
Willow Bioscience CEO Dr Chris Savilejoined Steve Darling from Proactive to announce a significantcollaboration agreement between Willow Biosciences andSuanfarma.
The partnership isfocused on optimizing cell line productivity for manufacturing ahigh-volume anti-infective Active Pharmaceutical Ingredient (API)using precision fermentation. Savile explained that Suanfarma willgain access to Willow Biosciences' proprietary strain optimizationtechnologies, enabling the development of a more cost-effectiveproduction process for the API.
Willow Biosciences will apply its strain engineering technologyplatform to facilitate cost-effective commercial production of the APIat Suanfarma's manufacturing facility.
Suanfarma is a contract development andmanufacturing organization (CDMO) with a strong track record andexpertise in fermentation, purification, and chemical synthesistechnologies. Its commitment to maintaining the highest qualitystandards in pharmaceutical and biotech manufacturing makes it anideal partner for this collaboration.
The agreement reflectsboth companies' dedication to advancing biotechnology solutionsfor pharmaceutical production.
ContactDetails
Proactive Investors
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.